Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | See remarks | May 01, 2023 | May 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date May 01, 2023 · Filed May 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 183,010 |
Ending reported balance
After 2023-05-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-05-01 · Exercise / conversion · Acquired 13,683 · Balance 187,026 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Row 2 · 2023-05-01 · Exercise / conversion · Acquired 3,750 · Balance 190,776 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Row 3 · 2023-05-01 · Exercise / conversion · Acquired 307 · Balance 191,083 F2: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Row 4 · 2023-05-02 · Sale · Disposed 8,073 · Balance 183,010 F4: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 357,645 |
Reported balance
After 2023-05-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-01 · Exercise / conversion · Disposed 13,683 · Balance 357,645 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 172,500 |
Reported balance
After 2023-05-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-01 · Exercise / conversion · Disposed 3,750 · Balance 172,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F5: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 50,612 |
Reported balance
After 2023-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-05-01 · Exercise / conversion · Disposed 307 · Balance 50,612 F3: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F6: Includes shares of Class B Common Stock that are subject to vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
F2: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F3: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F4: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F5: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.
F6: Includes shares of Class B Common Stock that are subject to vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 8,073 | $1.15 | $9,259.73 |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,010 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| May 01, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · derivative · entry 7 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,612 Underlying: Class A Common Stock · 307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F6 · price: Includes shares of Class B Common Stock that are subject to vesting conditions. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| May 01, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · derivative · entry 6 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,500 Underlying: Class A Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F5 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. F5 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. Read SEC document |
| May 01, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 13,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,645 Underlying: Class A Common Stock · 13,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| May 01, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| May 01, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| May 01, 2023 Filed May 5, 2023 00:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 13,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014600 · form4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 8,732 | $1.27 | $11,080.91 |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,343 F5 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · derivative · entry 7 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,919 Underlying: Class A Common Stock · 307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F7 · price: Includes shares of Class B Common Stock that are subject to vesting conditions. F4 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · derivative · entry 6 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,250 Underlying: Class A Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. F6 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments, which began on April 1, 2023. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 13,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,328 Underlying: Class A Common Stock · 13,684 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F4 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 22:38 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 13,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-012625 · form4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 24, 2023 21:13 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 180,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-011321 · form4.xml · derivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Class A Common Stock · 180,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The RSUs vest in 48 equal monthly installments beginning on April 1, 2023. F2 · derivative.expiration_date: The RSUs vest in 48 equal monthly installments beginning on April 1, 2023. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 7,326 | $1.33 | $9,736.25 |
DisclosureSEC source: 0001127602-23-008805 · form4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,334 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008805 · form4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,226 Underlying: Class A Common Stock · 307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 13,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008805 · form4.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,012 Underlying: Class A Common Stock · 13,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008805 · form4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 13,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008805 · form4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,683 of the RSUs was satisfied on March 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 6,470 | $2.15 | $13,904.03 |
DisclosureSEC source: 0001127602-23-003407 · form4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,670 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003407 · form4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,533 Underlying: Class A Common Stock · 306 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 13,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003407 · form4.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,695 Underlying: Class A Common Stock · 13,684 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003407 · form4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 13,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003407 · form4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on February 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 23:27 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 7,900 | $1.56 | $12,292.40 |
DisclosureSEC source: 0001127602-23-001108 · form4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,150 F4 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 23:27 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001108 · form4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,839 Underlying: Class A Common Stock · 307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 23:27 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 15,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001108 · form4.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,379 Underlying: Class A Common Stock · 15,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 23:27 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001108 · form4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F3 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 23:27 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 15,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-001108 · form4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 15,350 of the RSUs was satisfied on January 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 02:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 6,176 | $1.94 | $11,999.97 |
DisclosureSEC source: 0000899243-22-037732 · doc4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,393 F3 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of securities. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037732 · doc4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,146 Underlying: Class A Common Stock · 307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F4 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 13,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037732 · doc4.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,729 Underlying: Class A Common Stock · 13,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037732 · doc4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 13,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037732 · doc4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on December 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 02:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 6,279 | $2.65 | $16,607.96 |
DisclosureSEC source: 0000899243-22-035327 · doc4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,912 F3 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of securities. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| November 01, 2022 Filed Nov 8, 2022 02:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035327 · doc4.xml · derivative · entry 5 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,453 Underlying: Class A Common Stock · 307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F5 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F6 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| November 01, 2022 Filed Nov 8, 2022 02:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 13,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035327 · doc4.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,079 Underlying: Class A Common Stock · 13,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F1 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F2 · derivative.underlying_shares: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F4 · balance_after: On October 7, 2022, the Reporting Person filed a Form 4 that reported holdings of 442,161 RSUs. At that time the Reporting Person held 454,429 RSUs. Read SEC document |
| November 01, 2022 Filed Nov 8, 2022 02:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035327 · doc4.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. Read SEC document |
| November 01, 2022 Filed Nov 8, 2022 02:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 13,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035327 · doc4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F1 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| October 06, 2022 Filed Oct 8, 2022 00:21 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 102,254 | $3.25 | $332,325.50 |
DisclosureSEC source: 0000899243-22-033326 · doc4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,534 F1 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 02:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 2,722 | $3.12 | $8,497.00 |
DisclosureSEC source: 0000899243-22-032863 · doc4.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,217 F4 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 03, 2022 Filed Oct 8, 2022 00:19 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 2,722 | $3.12 | $8,497.00 |
DisclosureSEC source: 0000899243-22-033325 · doc4a.xml · nonDerivative · entry 3 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,788 F4 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 02:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 490,805 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032863 · doc4.xml · derivative · entry 6 Fallon Marie E. · CIK 0001883686 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F6 · balance_after: Includes restricted stock units that are subject to vesting conditions. Includes 190,000 restricted stock units that were acquired after November 17, 2021. Read SEC document |
| October 01, 2022 Filed Oct 8, 2022 00:19 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 226,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033325 · doc4a.xml · derivative · entry 6 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,161 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F6 · balance_after: Includes RSUs that are subject to vesting conditions. Includes 190,000 RSUs that were acquired after November 17, 2021. Read SEC document |
| October 01, 2022 Filed Oct 8, 2022 00:19 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 226,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033325 · doc4a.xml · nonDerivative · entry 2 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 02:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 6,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032863 · doc4.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,760 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 02:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 6,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032863 · doc4.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| September 30, 2022 Filed Oct 8, 2022 00:19 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 6,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033325 · doc4a.xml · derivative · entry 4 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,760 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Excludes RSUs, which were previously reported as shares of Class B Common Stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports. Read SEC document |
| September 30, 2022 Filed Oct 8, 2022 00:19 UTC Amendment | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 6,134 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033325 · doc4a.xml · nonDerivative · entry 1 Fallon Marie E. · CIK 0001883686 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.